Immunitybio Inc

IBRX remains in a Stage 4 decline with confirmed support failure and a lower-high/lower-low regime. Medium-term bias is bearish, reinforced by Support Failure and Bearish Pivot Point patterns. Short-term conditions favor further downside as price rejects at declining 9EMA/20EMA and trades below the 50 SMA. The Momentum + EPS strategy calls for participating in the downtrend by selling into shallow rallies around the EMAs for disciplined entries. Long-term uptrend remains intact above the 200 DMA, anchoring structural polarity.

• ↑ANKTIVA Phase 3 trial efficacy drove an 8.92% jump post-ASCO presentation.
• ↑Analyst consensus ‘Strong Buy’ with $13 average target implies ~47.9% upside.
• ↓Q1 2026 net loss of $0.08/share missed estimates, underlining weak profitability.